[Neurogenic diabetes insipidus].
D001581:Benzothiadiazines; D002747:Chlorpropamide / Q000627:therapeutic use; D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use; D003919:Diabetes Insipidus / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D004232:Diuretics; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000293:injuries / Q000503:physiopathology*; D010900:Pituitary Diseases / Q000150:complications; D011183:Postoperative Complications; D011379:Prognosis; D011448:Prostaglandin Antagonists / Q000627:therapeutic use; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use; D014667:Vasopressins / Q000172:deficiency*
D001581:Benzothiadiazines; D004232:Diuretics; D011448:Prostaglandin Antagonists; D049993:Sodium Chloride Symporter Inhibitors; D014667:Vasopressins; D003894:Deamino Arginine Vasopressin; D002747:Chlorpropamide
Diabetes insípida neurogénica.